Crestor® (rosuvastatin)
Crestor®, rosuvastatin
is on the approved list in
the Netherlands and is available for international shipment.
Therapeutic indications
CRESTOR is indicated for patients with
primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia)
or mixed dyslipidemia (type IIb) as an adjunct to diet when response to
diet and exercise is inadequate.
CRESTOR reduces elevated LDL-cholesterol,
total cholesterol, triglycerides and ApoB, and increases HDL-cholesterol.
CRESTOR is also indicated in patients with
homozygous familial hypercholesterolemia, either alone or as an adjunct to
diet and other lipid lowering treatments (e.g. LDL aphaeresis).
Crestor® is available for international
importation
on patient label.
Important Notice
Meerburg Pharmacy neither promotes nor encourages the use and importation
of medications in any way.
View prescribing information leaflet.
(english) (Acrobat)
Each country has its
own laws and regulations for the importation of medication to protect
their citizens.
e.g. USA: http://www.customs.gov/xp/cgov/travel/alerts/medication_drugs.xml
e.g. Australia: http://www.health.gov.au/tga/docs/html/bringmed/persimp.htm
e.g. Canada (EN): http://www.hc-sc.gc.ca/hpfb-dgpsa/inspectorat/imp_hum_drug_per_use_enf_dir_tc_e.html
e.g. Canada (FR): http://www.hc-sc.gc.ca/hpfb-dgpsa/inspectorat/imp_hum_drug_per_use_enf_dir_tc_f.html
Ordering
Crestor® is available for international shipment.
Before ordering Crestor ® it is important that
you read the package
leaflet and discuss any questions you might have with your
doctor.
As Crestor® is probably not approved in your country
yet, it can be dispensed in situations where a patient cannot be
treated suitably with approved medication:
- The specialist has thorough experience in the
treatment of Alzheimer's disease and is well aware of the
therapeutical indications, contra-indications, precautions, drug
interactions and side effects of Crestor® and has informed the
patient that this medication is unapproved (informed consent);
for example see below*)
- The doctor declares that he is aware that Crestor®
is not on the approved list and that no effective alternative
treatment is available domestically (no approved alternatives);
for example see below *)
- The patient declares that Crestor® is for own use
and provide the name and address of the qualified doctor (in your
country) responsible for evaluation of the treatment with Crestor® (declaration);
(on order form)
- If you meet the above mentioned conditions and
you have a valid prescription, you can order Crestor®
Meerburg Pharmacy will
guarantee
that the recipient will receive the Crestor®
medication
or else no charges will be made.
We cannot be
responsible for knowing all aspects of the taxes and duties which may be
applied in the country to which we are shipping. In some cases, duties and
taxes may be as much as as 75% of the total value of the shipment (India).
Some countries levy VAT on personal importation . Those costs are the
responsibility of the recipient.
| *)
Example of doctors declaration:
This
doctor’s declaration must show your name and date of birth. Your
doctor may choose his own words and must use his
letterhead. An example:
To
whom it may concern:
This
is to certify that I have prescribed the drug Crestor®for my
patient ________________, DOB _________.
I
realize that this medication is not available in __________ and that
is classified as an investigational drug. I have informed my patient
of this fact and have discussed with him the possible drug
interactions and side effects which could occur. My patient will be
under my constant care while she is taking this medication.
Should
you have any further questions for me do not hesitate to contact me.
Sincerely,
______________
, M.D.
|
Electronic order forms:
Crestor®
secure online order form 
SSL 128 bit secure
If you get an error, your browser might not support 128
bit secure data transmission. Please select the standard form or adjust
your browser.
Crestor
standard security
Fax order form:
Crestor®
fax order form
Email service: I
have specific questions about Crestor (click here)
Scientific Publications :
Other information:
7 November 2002
ASTRAZENECA’S NEW STATIN, CRESTOR™,
RECEIVES FIRST APPROVAL IN EUROPE - Other European markets should follow
in 2003
AstraZeneca announced today it has received the first approval for
CRESTOR™ (rosuvastatin) 10-40 mg from the Medicines Evaluation Board (MEB)
in the Netherlands for the management of primary hypercholesterolaemia and
mixed dyslipidaemia.
Sir Tom McKillop, Chief Executive of AstraZeneca, said, "We are
delighted to have received this first approval of CRESTOR, which
represents another milestone for the company. CRESTOR is an outstanding
product that will enable more patients across the world to reach their
target LDL cholesterol levels, and aid in the global fight against
coronary heart disease.”
The Netherlands MEB will act as the Reference Member State for the
European Mutual Recognition Procedure leading to further approvals in 16
other countries in Europe--beginning in the first half of 2003. CRESTOR is
also awaiting approval in the USA, Japan and in other markets.
The clinical development programme for CRESTOR now involves over 15,000
patients and includes a number of head-to-head comparative studies. In
multiple clinical studies, CRESTOR has been shown to be more effective in
lowering LDL-cholesterol (LDL-C or ‘bad’ cholesterol) than the
currently prescribed statins. It has demonstrated reductions of 52% to 63%
across the dose range, and compared to the same doses of atorvastatin,
CRESTOR provided a significant 8.4% greater reduction in LDL-C. CRESTOR
10mg gets significantly more patients to their European LDL-C goal than
atorvastatin 10mg (82% v 51% respectively), simvastatin 20mg (80% v 48%)
and pravastatin 20mg (80% v 16%). In addition to the dramatic reductions
seen in LDL-C, CRESTOR produces a significant increase in HDL-C
(‘good’ cholesterol), as well as reducing total cholesterol and
triglycerides.
The excellent efficacy of CRESTOR, together with a safety profile,
which the company believes is comparable to the marketed statins, will
position CRESTOR as a highly effective competitor in the global statin
market, estimated to be worth more than $18 billion and growing at a rate
of about 20 per cent annually.
Dr Hamish Cameron, Vice President and Head of Cardiovascular Therapy
Area at AstraZeneca, said, “Despite many medical advances,
hypercholesterolaemia remains poorly controlled. Approximately half of the
people on cholesterol lowering therapy are still not reaching their
cholesterol targets and are at risk of heart attacks and strokes. With the
efficacy we’ve seen in clinical studies, CRESTOR could make a real
difference to these patients’ lives.”
A copy of the English version of the approved label for CRESTOR™ in
The Netherlands (rosuvastatin) can be found at www.astrazeneca.com/redirector/index.asp?id=6
Details on the approval of CRESTOR™ (rosuvastatin) will be provided
by Dr Hamish Cameron at 08.30 GMT today as a part of the company’s
Annual Business Review. Details of this event can be found at www.astrazeneca.com/redirector/index.asp?id=5
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of ethical (prescription)
pharmaceuticals and the supply of healthcare services. It is one of the
top five pharmaceutical companies in the world with healthcare sales of
over $16.4 billion and leading positions in sales of gastrointestinal,
oncology, anaesthesia including pain management, cardiovascular, central
nervous system (CNS) and respiratory products. AstraZeneca has more than
40 years experience in cardiovascular medicine and aims to increase
lifespan and improve quality of life by reducing the risk, prevalence and
impact of cardiovascular disease. AstraZeneca has a comprehensive
cardiovascular portfolio including CRESTOR, ATACAND, ZESTRIL, TENORMIN,
SELOKEN ZOK /TOPROL XL AND PLENDIL. This heritage is complemented by an
innovative pipeline including the first oral direct thrombin inhibitor,
EXANTA, and a novel treatment for type 2 diabetes / metabolic syndrome,
GALIDA.
|
